Some groups have focused on the detection and management of subjective memory impairment (SMI) as the stage that precedes mild cognitive impairment (MCI). However, there have been few clinical studies that have examined biomarkers of SMI to date.
Purpose
To investigate the differences in glucose metabolism as a prodromal marker of dementia in patients with SMI, MCI, and healthy controls using brain F-18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET).
Material and Methods
Sixty-eight consecutive patients with SMI, 47 patients with MCI, and 42 age-matched healthy subjects were recruited. All subjects underwent FDG-PET and detailed neuropsychological testing. FDG-PET images were analyzed using the statistical parametric mapping (SPM) program.
Results
FDG-PET analysis showed glucose hypometabolism in the periventricular regions of patients with SMI and in the parietal, precentral frontal, and periventricular regions of patients with MCI compared with healthy controls. Interestingly, hypometabolism on FDG-PET was noted in the parietal and precentral frontal regions in MCI patients compared to SMI patients.
Conclusion
The results suggest that hypometabolism in the periventricular regions as seen on FDG-PET may play a role as a predictive biomarker of pre-dementia, and the extension of reduced glucose metabolism into parietal regions likely reflects progression of cognitive deterioration.
MosconiLPupiADe CristofaroMT. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer’s disease. J Nucl Med2004; 45: 382–392.
2.
MosconiLPupiADe LeonMJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer’s disease. Ann N Y Acad Sci2008; 1147: 180–195.
3.
WinbladBPalmerKKivipeltoM. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med2004; 256: 240–246.
4.
VisserPJKesterAJollesJ. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology2006; 67: 1201–1207.
HanninenTHallikainenMTuomainenS. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. Acta Neurol Scand2002; 106: 148–154.
8.
ScheefLSpottkeADaerrM. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology2012; 79: 1332–1339.
ReisbergBShulmanMBTorossianC. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement2010; 6: 11–24.
11.
JessenFWieseBBachmannC. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry2010; 67: 414–422.
12.
VisserPJVerheyFKnolDL. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol2009; 8: 619–627.
13.
ErkSSpottkeAMeisenA. Evidence of neuronal compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry2011; 68: 845–852.
14.
MinoshimaSFreyKAFosterNL. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr1995; 19: 541–547.
15.
FormanSDCohenJDFitzgeraldM. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn Reson Med1995; 33: 636–647.
16.
BraakHBraakE. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol1996; 92: 197–201.
17.
MorrisJCStorandtMMcKeelDWJr. Cerebral amyloid deposition and diffuse plaques in “normal” aging: Evidence for presymptomatic and very mild Alzheimer’s disease. Neurology1996; 46: 707–719.
18.
StewartRDufouilCGodinO. Neuroimaging correlates of subjective memory deficits in a community population. Neurology2008; 70: 1601–1607.
19.
MosconiL. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging2005; 32: 486–510.
20.
MosconiLDe SantiSLiJ. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging2008; 29: 676–692.
21.
de LeonMJConvitAWolfOT. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA2001; 98: 10966–10971.
22.
ChetelatGDesgrangesBde la SayetteV. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease?Neurology2003; 60: 1374–1377.
23.
NestorPJFryerTDSmielewskiP. Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol2003; 54: 343–351.
24.
DelacourteADavidJPSergeantN. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology1999; 52: 1158–1165.
25.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
26.
ArriagadaPVMarzloffKHymanBT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology1992; 42: 1681–1688.
27.
GiannakopoulosPHofPRMottierS. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol1994; 87: 456–468.
28.
JagustWGitchoASunF. Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol2006; 59: 673–681.
29.
MosconiLDe SantiSBrysM. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry2008; 63: 609–618.
30.
DufouilCFuhrerRAlperovitchA. Subjective cognitive complaints and cognitive decline: consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc2005; 53: 616–621.
31.
HaleyAPHothKFGunstadJ. Subjective cognitive complaints relate to white matter hyperintensities and future cognitive decline in patients with cardiovascular disease. Am J Geriatr Psychiatry2009; 17: 976–985.
32.
de GrootJCde LeeuwFEOudkerkM. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology2001; 56: 1539–1545.
33.
HawkesCAGathererMSharpMM. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-beta from the mouse brain. Aging Cell2013; 12: 224–236.
34.
WellerROSubashMPrestonSD. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol2008; 18: 253–266.
35.
RoherAEKuoYMEshC. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer’s disease. Mol Med2003; 9: 112–122.
36.
TomuraNSasakiKKidaniH. Reduced perfusion reserve in Leukoaraiosis demonstrated using acetazolamide challenge 123I-IMP SPECT. J Comput Assist Tomogr2007; 31: 884–887.
